Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.
Palladini
Giovanni
G
Russo
Paola
P
Nuvolone
Mario
M
Lavatelli
Francesca
F
Perfetti
Vittorio
V
Obici
Laura
L
Merlini
Giampaolo
G
D000686:Amyloidosis / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007147:Immunoglobulin Light Chains; D008558:Melphalan / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007147:Immunoglobulin Light Chains; D003907:Dexamethasone; D008558:Melphalan